Form 4: Catalyst Pharma CEO's Stock Activity Post-RSU Vesting

Catalyst Pharmaceuticals CEO Richard J. Daly reported acquiring shares through a routine restricted stock unit vesting and subsequent tax-related sale.

Summary

• Richard J. Daly, President and CEO, and a Director of Catalyst Pharmaceuticals, Inc. (CPRX), reported changes in his beneficial ownership.
• On January 5, 2026, Daly acquired 42,105 shares of common stock through the vesting of restricted stock units (RSUs).
• Concurrently, 10,577 shares of common stock were disposed of to satisfy applicable withholding taxes related to the RSU vesting.
• Following these transactions, Daly directly beneficially owns 271,266 shares of common stock.
• The transaction involved the second tranche of RSUs vesting, which was delivered on January 5, 2026.
• Daly continues to beneficially own 2,618,539 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects a routine, pre-scheduled compensation event (RSU vesting) for the CEO, indicating continued alignment of management's interests with the company. The tax-related sale is a standard practice and does not imply negative sentiment.

Positives

• The vesting of 42,105 restricted stock units indicates a scheduled compensation event, aligning management's interests with long-term company performance.
• The continued significant beneficial ownership of 2,618,539 RSUs by the CEO demonstrates ongoing commitment to the company's future.

Negatives

• A disposition of 10,577 shares occurred to cover tax obligations, which reduces the CEO's direct shareholding, although this is a common practice for RSU vesting.

Future Outlook

The remaining restricted stock units are scheduled to vest in equal tranches on January 1, 2027, January 1, 2028, and January 1, 2029, with shares of common stock required to be delivered within sixty days of vesting.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, specifically the vesting of restricted stock units. Such transactions are common across the pharmaceutical industry and other sectors where equity-based compensation is a standard practice for aligning executive incentives with shareholder value.

Stakeholder Impact

• Shareholders: The vesting and subsequent tax-related sale by the CEO is a routine compensation event and is unlikely to have a significant direct impact on share price or company strategy. It reinforces the existing executive compensation structure.
• Employees: No direct impact mentioned.

Next Steps

• Future tranches of restricted stock units are scheduled to vest on January 1, 2027, January 1, 2028, and January 1, 2029.

Key Dates

Keywords

Catalyst Pharmaceuticals, CPRX, Richard J. Daly, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Beneficial Ownership, CEO Stock, Pharmaceuticals